My Portfolio

Sarepta Therapeutics Inc SRPT:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD

After Hours: Last | 7:36 PM EDT

16.19

-0.05 (-0.31%)

Volume

1,270,429

16.24

-0.01 (-0.06%)

Volume

2,244,017

52 week range

10.42 - 43.92

Open16.25
Day High16.52
Day Low16.10
Prev Close16.25
52 Week High43.92
52 Week High Date06/09/25
52 Week Low10.42
52 Week Low Date07/24/25

Latest On Sarepta Therapeutics Inc

How CNBC Cures is bringing rare disease stories to a national audienceMarch 20, 2026CNBC.com
FDA reversals leave investors worrying about the fates of other experimental drugsMarch 6, 2026CNBC.com
FDA watchers warn of agency in 'chaos' and risk to America's healthMarch 3, 2026CNBC.com
Stocks making big midday moves: GameStop, Booz Allen, CoreWeave & more January 26, 2026CNBC.com
Stocks making big moves midday: Uber, Hertz, Norwegian Cruise, Yum, PalantirNovember 4, 2025CNBC.com
Stocks making the biggest moves premarket: Uber, Sarepta, Palantir and moreNovember 4, 2025CNBC.com
It's a high-risk trade, but this biotech down 80% this year could be a buyOctober 31, 2025CNBC.com
Stocks making the biggest moves midday: Starbucks, FICO, Acadia HealthcareOctober 2, 2025CNBC.com
Stocks making the biggest midday moves: Oracle, Apple, Metsera, Kenvue and moreSeptember 22, 2025CNBC.com
Monday's biggest analyst calls: Nvidia, Apple, Netflix, Amazon, Nike and moreSeptember 22, 2025CNBC.com

Key Stats

Market Cap1.715B
Shares Out105.58M
10 Day Average Volume2.81M
Dividend-
Dividend Yield-
Beta0.21

Latest On Sarepta Therapeutics Inc

How CNBC Cures is bringing rare disease stories to a national audienceMarch 20, 2026CNBC.com
FDA reversals leave investors worrying about the fates of other experimental drugsMarch 6, 2026CNBC.com
FDA watchers warn of agency in 'chaos' and risk to America's healthMarch 3, 2026CNBC.com
Stocks making big midday moves: GameStop, Booz Allen, CoreWeave & more January 26, 2026CNBC.com
Stocks making big moves midday: Uber, Hertz, Norwegian Cruise, Yum, PalantirNovember 4, 2025CNBC.com
Stocks making the biggest moves premarket: Uber, Sarepta, Palantir and moreNovember 4, 2025CNBC.com
It's a high-risk trade, but this biotech down 80% this year could be a buyOctober 31, 2025CNBC.com
Stocks making the biggest moves midday: Starbucks, FICO, Acadia HealthcareOctober 2, 2025CNBC.com
Stocks making the biggest midday moves: Oracle, Apple, Metsera, Kenvue and moreSeptember 22, 2025CNBC.com
Monday's biggest analyst calls: Nvidia, Apple, Netflix, Amazon, Nike and moreSeptember 22, 2025CNBC.com

KEY STATS

Open16.25
Day High16.52
Day Low16.10
Prev Close16.25
52 Week High43.92
52 Week High Date06/09/25
52 Week Low10.42
52 Week Low Date07/24/25
Market Cap1.715B
Shares Out105.58M
10 Day Average Volume2.81M
Dividend-
Dividend Yield-
Beta0.21

RATIOS/PROFITABILITY

EPS (TTM)0.11
P/E (TTM)149.40
Fwd P/E (NTM)17.44
EBITDA (TTM)223.963M
ROE (TTM)4.91%
Revenue (TTM)2.184B
Gross Margin (TTM)70.45%
Net Margin (TTM)2.98%
Debt To Equity (MRQ)55.69%

EVENTS

Earnings Date08/04/2026(est)
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Content From Our Affiliates

FDA issues draft guidance to help accelerated cell, gene therapies for patientsJune 2, 2026TipRanks
J.P. Morgan Remains a Hold on Sarepta Therapeutics (SRPT)May 19, 2026TipRanks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Zoetis (ZTS), Sarepta Therapeutics (SRPT) and GoodRx Holdings (GDRX)May 15, 2026TipRanks
Sarepta price target lowered to $19 from $20 at Evercore ISIMay 15, 2026TipRanks
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Sarepta Therapeutics (SRPT) and Surgery Partners (SGRY)May 13, 2026TipRanks

Profile

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates...

M. Kathleen Behrens Ph.D.

Independent Chairwoman of the Board

Douglas Ingram Esq., J.D.

Chief Executive Officer, Director

Ian Estepan

President, Chief Operating Officer

Ryan Wong

Chief Financial Officer, Executive Vice President

Cristin Rothfuss

Executive Vice President, General Counsel

Address

215 First Street, Suite 415

Cambridge, MA

02142

United States

https://www.sarepta.com/